Senhwa Biosciences, Inc.
CX-4945 in Viral Community Acquired Pneumonia
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT06202521
- Locations
- π¨π³
Far Eastern Memorial Hospital, New Taipei City, Taiwan
π¨π³Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
π¨π³National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan
A Study of Silmitasertib (CX-4945) in Healthy Subject
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05817708
- Locations
- π¨π³
Taipei Medical University Hospital, Taipei, Taiwan
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04890613
- Locations
- πΊπΈ
Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈUniversity of California, Los Angeles, Santa Monica, California, United States
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04663737
- Locations
- πΊπΈ
Center for Advanced Research and Education, Gainesville, Georgia, United States
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03897036
- Locations
- πΊπΈ
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
πΊπΈH. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States
πΊπΈUniversity of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT02128282
- Locations
- πΊπΈ
University of Colorado- Denver, Aurora, Colorado, United States
π°π·Seoul National University Hospital, Seoul, Korea, Republic of
πΊπΈTexas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States